New MGA Paper Investigates the Economic and Budgetary Effects of the BLOCKING Act
This report examines the BLOCKING Act and why it is a misguided attempt at promoting generic drug competition. The report points out that the bill would reduce the incentive for generic firms to challenge brand drug patents, thus delaying generic entry for some drugs. The lost savings from the delay of one generic could easily exceed the estimated gains that the BLOCKING Act is purported to achieve.
